Martin F Fey
ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Kunstfeld R, Moser E, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori F, Pfeilstöcker M, Raut C, Michielin O, Meran J, Lenz H, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer P, Markham M, Markman B, Mayerhoefer M, Remick S, Robson M, Rutkowski P, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber J, Wildiers H, Strasser F, Stiefel F, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll H, Schnipper L, Sessa C, Shapiro C, Steele J, Sternberg C, Yarden Y, Dittrich C, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close J, Coiffier B, Connolly R, Coupland S, Banerjee S, Awada A, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz J, Österlund P, Pavlidis N, Purkalne G, De Petris L, De Santis M, de Vries E, Hahn S, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones D, Jost L, Keilholz U, Khan S, Kiss A, Grothey A, Gopalan P, Dizon D, Duff J, Duska L, Eniu A, Ernstoff M, Felip E, Fey M, Gilbert J, Girard N, Glaudemans A, Köhne C. ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. ESMO Open 2016; 1:e000097.
29.09.2016ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
29.09.2016ESMO Open 2016; 1:e000097
Kunstfeld Rainer, Moser Elizabeth Charlotte, Mountzios Giannis, Moynihan Timothy, Nielsen Torsten, Ohe Yuichiro, Öberg Kjell, Palumbo Antonio, Peccatori Fedro Alessandro, Pfeilstöcker Michael, Raut Chandrajit, Michielin Olivier, Meran Johannes G, Lenz Heinz-Josef, Lichtman Stuart, Licitra Lisa, Lion Thomas, Litière Saskia, Liu Lifang, Loehrer Patrick J, Markham Merry Jennifer, Markman Ben, Mayerhoefer Marius, Remick Scot C, Robson Mark, Rutkowski Piotr, Stupp Roger, Sullivan Richard, Tabernero Josep, Travado Luzia, Verheij Marcel, Voest Emile, Vokes Everett, Von Roenn Jamie, Weber Jeffrey S, Wildiers Hans, Strasser Florian, Stiefel Friedrich, Salgado Roberto, Schapira Lidia, Schernhammer Eva, Schlumberger Martin, Schmoll Hans-Joachim, Schnipper Lowell, Sessa Cristiana, Shapiro Charles L, Steele Julie, Sternberg Cora N, Yarden Yosef, Dittrich Christian, Bhatia Smita, Bogaerts Jan, Buckner Jan, Cardoso Fatima, Casali Paolo, Chu Edward, Close Julia Lee, Coiffier Bertrand, Connolly Roisin, Coupland Sarah, Banerjee Susana, Awada Ahmad, Kosty Michael, Jezdic Svetlana, Pyle Doug, Berardi Rossana, Bergh Jonas, El-Saghir Nagi, Lotz Jean-Pierre, Österlund Pia, Pavlidis Nicholas, Purkalne Gunta, De Petris Luigi, De Santis Maria, de Vries Elisabeth G E, Hahn Stephen M, Hanna Diana, Herold Christian, Herrstedt Jørn, Homicsko Krisztian, Jones Dennie V, Jost Lorenz, Keilholz Ulrich, Khan Saad, Kiss Alexander, Grothey Axel, Gopalan Priya K, Dizon Don S, Duff Jennifer, Duska Linda R, Eniu Alexandru, Ernstoff Marc, Felip Enriqueta, Fey Martin F, Gilbert Jill, Girard Nicolas, Glaudemans Andor W J M, Köhne Claus-Henning
Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
Pagani O, Goldhirsch A, Coates A, Fey M, Collins J, Thürlimann B, Lindtner J, Holmberg S, Castiglione-Gertsch M, Gelber R, Price K, International Breast Cancer Study Group (IBCSG). Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century. Breast Cancer Res Treat 2009; 117:319-24.
01.09.2009Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century
01.09.2009Breast Cancer Res Treat 2009; 117:319-24
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Fey Martin F, Collins John, Thürlimann Beat, Lindtner Jurij, Holmberg Stig B, Castiglione-Gertsch Monica, Gelber Richard D, Price Karen N, International Breast Cancer Study Group (IBCSG)
Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
Pagani O, Goldhirsch A, Coates A, Forbes J, Murray E, Fey M, Thürlimann B, Lindtner J, Collins J, Crivellari D, Holmberg S, Gelber R, Price K, Castiglione-Gertsch M, Simoncini E, Gelber S, International Breast Cancer Study Group. Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93. Breast Cancer Res Treat 2009; 116:491-500.
01.08.2009Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93
01.08.2009Breast Cancer Res Treat 2009; 116:491-500
Pagani Olivia, Goldhirsch Aron, Coates Alan S, Forbes John F, Murray Elizabeth, Fey Martin F, Thürlimann Beat, Lindtner Jurij, Collins John, Crivellari Diana, Holmberg Stig B, Gelber Richard D, Price Karen N, Castiglione-Gertsch Monica, Simoncini Edda, Gelber Shari, International Breast Cancer Study Group
The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
Karlsson P, Goldhirsch A, Gelber R, Forbes J, Crivellari D, Thürlimann B, Fey M, Holmberg S, Collins J, Lindtner J, Murray E, Gusterson B, Castiglione-Gertsch M, Coates A, Price K, Cole B, Wallgren A. The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer. JCO 2007; 25:2019-26.
20.05.2007The role of the number of uninvolved lymph nodes in predicting locoregional recurrence in breast cancer
20.05.2007JCO 2007; 25:2019-26
Karlsson Per, Goldhirsch Aron, Gelber Richard D, Forbes John F, Crivellari Diana, Thürlimann Beat, Fey Martin F, Holmberg Stig B, Collins John P, Lindtner Jurij, Murray Elizabeth, Gusterson Barry A, Castiglione-Gertsch Monica, Coates Alan S, Price Karen N, Cole Bernard F, Wallgren Arne
Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI
Gruber G, Goldhirsch A, Coates A, Gelber R, Fey M, Simoncini E, Thürlimann B, Carbone A, Crivellari D, Collins J, Golouh R, Lindtner J, Holmberg S, Rudenstam C, Castiglione-Gertsch M, Price K, Nasi M, Bonetti M, International Breast Cancer Study Group. Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI. JCO 2005; 23:7089-97.
01.10.2005Prognostic value of extracapsular tumor spread for locoregional control in premenopausal patients with node-positive breast cancer treated with classical cyclophosphamide, methotrexate, and fluorouracil: long-term observations from International Breast Cancer Study Group Trial VI
01.10.2005JCO 2005; 23:7089-97
Gruber Günther, Goldhirsch Aron, Coates Alan S, Gelber Richard D, Fey Martin F, Simoncini Edda, Thürlimann Beat, Carbone Antonino, Crivellari Diana, Collins John, Golouh Rastko, Lindtner Jurij, Holmberg Stig B, Rudenstam Carl-Magnus, Castiglione-Gertsch Monica, Price Karen N, Nasi M Laura, Bonetti Marco, International Breast Cancer Study Group
Pneumococcal vaccination in splenectomised cancer patients
Omlin A, Mühlemann K, Fey M, Pabst T. Pneumococcal vaccination in splenectomised cancer patients. European journal of cancer (Oxford, England : 1990) 2005; 41:1731-4.
01.08.2005Pneumococcal vaccination in splenectomised cancer patients
01.08.2005European journal of cancer (Oxford, England : 1990) 2005; 41:1731-4
Omlin Aurelius, Mühlemann Kathrin, Fey Martin F, Pabst Thomas
Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
Colleoni M, Thürlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates A, Price K, Fey M, Collins J, Zahrieh D, Gelber R, Holmberg S, Mattsson J, Rudenstam C, Lindtner J, Erzen D, Snyder R, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. JCO 2005; 23:1390-400.
01.03.2005Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience
01.03.2005JCO 2005; 23:1390-400
Colleoni Marco, Thürlimann Beat, Crivellari Diana, Murray Elizabeth, Mendiola Caesar, Pagani Olivia, Castiglione-Gertsch Monica, Coates Alan S, Price Karen, Fey Martin F, Collins John, Zahrieh David, Gelber Richard D, Holmberg Stig B, Mattsson Jan E, Rudenstam Carl-Magnus, Lindtner Jurij, Erzen Darja, Snyder Raymond, Goldhirsch Aron
Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11.
01.02.2005Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)
01.02.2005Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005; 23:705-11
Ghielmini Michele, Cerny Thomas, Bargetzi Mario, Ketterer Nicolas, Stahel Rolf, Pichert Gabriella, Schefer Hubert, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Bertoni Francesco, Cogliatti Sergio, Schmitz Shu-Fang Hsu, Swiss Group for Clinical Cancer Research
Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. Blood 2004; 103:4416-23.
15.06.2004Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule
15.06.2004Blood 2004; 103:4416-23
Ghielmini Michele, Vorobiof Daniel, Bargetzi Mario, Lohri Andreas, Helg Claudine, Kovacsovics Tibor, Stupp Roger, Zucca Emanuele, Hess Urs, Peccatori Fedro, Martinelli Giovanni, Betticher Daniel C, Fey Martin F, Waltzer Ursula, Hummerjohann Jörg, Pichert Gabriella, Cogliatti Sergio B, Schmitz Shu-Fang Hsu, Cerny Thomas